Press releases

InDex Pharmaceuticals Holding AB (publ) interim report January – September 2016

Initial public offering and listing on Nasdaq First North Stockholm Period July – September 2016  Revenues amounted to MSEK 0.0 (0.0)  Operating result amounted to MSEK -6.6 (-7.5)  Result after tax amounted to MSEK -7.4 (-7.2), corresponding to SEK -0.25 per share (-0.24) before and after dilution  Cas...

Read more

InDex Pharmaceuticals gets new patent granted in the US

November 3, 2016 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be granted by the United States Patent and Trademark Office (USPTO). The patent provides additional protection for the use of certain dosage regimens of c...

Read more

Results from InDex Pharmaceuticals’ COLLECT study well received at UEGW

October 18, 2016 – Additional analyses of data from COLLECT – a clinical study of InDex Pharmaceuticals Holding AB’s (publ) lead drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis – was orally presented and met with great interest at the United European Gastroe...

Read more

Trading in InDex Pharmaceutical’s shares starts October 11

October 6, 2016 - InDex Pharmaceuticals Holding AB (publ) has met the requirements for listing on Nasdaq First North Stockholm and the marketplace has now given its formal approval to the company. First day of trading in the share is Tuesday, October 11, 2016. The share will be traded under the ticker...

Read more

InDex Pharmaceuticals plans Initial Public Offering

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL August 19, 2016 – The Board of InDex Pharmaceuticals today announced its intention to proceed w...

Read more

InDex Pharmaceuticals publishes results from COLLECT study

July 13, 2016 - InDex Pharmaceuticals AB today announced the publication of the results from COLLECT, a clinical study of the Toll-like receptor 9 (TLR9) agonist cobitolimod as a first-in-class treatment for patients with moderate to severe ulcerative colitis (UC). The paper, published in the peer-reviewed...

Read more

InDex Pharmaceuticals receives approval of the International Nonproprietary Name (INN) cobitolimod for their lead drug candidate Kappaproct®

February 10, 2016 - InDex Pharmaceuticals AB today announced that the World Health Organization (WHO) has recommended cobitolimod as the International Nonproprietary Name (INN) for Index´s lead drug candidate Kappaproct®, which is a first-in-class Toll-like receptor (TLR) 9 agonist in late-stage clinical d...

Read more